BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
61.73
+0.62 (1.01%)
At close: Feb 27, 2026, 4:00 PM EST
59.31
-2.42 (-3.92%)
After-hours: Feb 27, 2026, 7:57 PM EST
BioMarin Pharmaceutical Stock Forecast
Stock Price Forecast
The 16 analysts that cover BioMarin Pharmaceutical stock have a consensus rating of "Buy" and an average price target of $87.94, which forecasts a 42.46% increase in the stock price over the next year. The lowest target is $55 and the highest is $119.
Price Target: $87.94 (+42.46%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioMarin Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 6 | 5 |
| Buy | 11 | 9 | 9 | 8 | 8 | 7 |
| Hold | 7 | 7 | 5 | 6 | 6 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 22 | 19 | 19 | 20 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $98 → $104 | Strong Buy | Maintains | $98 → $104 | +68.48% | Feb 26, 2026 |
| Bernstein | Bernstein | Buy Maintains $90 → $94 | Buy | Maintains | $90 → $94 | +52.28% | Feb 25, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $106 → $86 | Strong Buy | Maintains | $106 → $86 | +39.32% | Feb 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $60 → $55 | Hold | Maintains | $60 → $55 | -10.90% | Feb 25, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $98 → $95 | Buy | Maintains | $98 → $95 | +53.90% | Feb 24, 2026 |
Financial Forecast
Revenue This Year
3.58B
from 3.22B
Increased by 11.04%
Revenue Next Year
3.91B
from 3.58B
Increased by 9.25%
EPS This Year
4.43
from 1.80
Increased by 146.32%
EPS Next Year
5.42
from 4.43
Increased by 22.17%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.1B | 4.8B | |||
| Avg | 3.6B | 3.9B | |||
| Low | 3.2B | 3.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.2% | 35.4% | |||
| Avg | 11.0% | 9.3% | |||
| Low | -1.7% | -10.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.97 | 8.19 | |||
| Avg | 4.43 | 5.42 | |||
| Low | 3.34 | 3.92 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 287.3% | 84.7% | |||
| Avg | 146.3% | 22.2% | |||
| Low | 85.7% | -11.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.